A Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies

• Status: Recruiting
• Trial end date: 2024-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluate the safety, pharmacokinetics and efficacy of HEC89736 in patients with Relapsed or Refractory B-cell Hematologic Malignancies

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sunshine Lake Pharma Co., Ltd.

Criteria

Inclusion Criteria:

• Age is over 18 years old

• Histologically or cytologically diagnosed patients with recurrent or refractory B-cell malignancies

• ECOG performance status (PS) 0 ~ 1

• Expected survival of > or = 3 months

Exclusion Criteria:

• The use of PI3Ks as the target of anti-tumor drugs progress (due to intolerance group)

• Received any other anti-cancer treatment within 4 weeks

• Unable to swallow, chronic diarrhea and intestinal obstruction, there are many factors that affect drug use and absorption

• Allergy, or known to have a history of allergy to the drug components